查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1371926

到 2030 年動脈粥狀硬化市場預測：按類型、治療方法、給藥途徑、通路、診斷、最終用戶和地區進行全球分析

Atherosclerosis Market Forecasts to 2030 - Global Analysis By Type, Treatment, Route of Administration, Distribution Channel, Diagnosis, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預測期內全球動脈粥狀硬化市場的年複合成長率為 4.24%。

動脈粥狀硬化是一個術語，用於描述由動脈內的膽固醇斑塊引起的動脈逐漸硬化和積聚。治療高血壓和高膽固醇的藥物即使無法阻止動脈硬化，也可以減少動脈硬化。這可以降低心臟病發作和中風的風險。搭橋手術使用來自身體其他部位的血管或合成管來繞過阻塞或狹窄的動脈。溶栓療法是將藥物注射到受影響的動脈中以溶解血栓的治療方法。斑塊旋切術是治療方法使用一端帶有刀片的導管去除動脈斑塊的治療方法。

根據歐洲心臟網路統計，歐洲每年有390萬人罹患心血管疾病，超過180萬人死亡。

心血管疾病患病增加

由於全球心血管疾病發生率的增加，預計該市場將發展得更快。由於久坐的生活方式，已開發國家心血管疾病的發生率最高。此外，老年人口的增加、久坐的生活方式導致心血管疾病的發病率更高，以及對現有治療方法的認知不斷增強，預計將推動所研究的市場。

與動脈硬化相關的副作用

動脈粥狀硬化會增加心臟病和中風等心血管事件的風險。這些事件可能導致死亡或嚴重殘疾。周邊動脈疾病可能是由四肢（尤其是腿部）動脈粥狀硬化引起的。這可能會導致不適、麻木和行走困難。這會降低動脈的彈性並增加血壓，從而對心血管系統帶來更大的壓力。預計市場成長將受到動脈粥狀硬化和低療效的不利影響的阻礙。

增加醫療保健基礎設施支出

增加醫療保健支出有助於加強基礎設施，是推動市場成長率的因素。隨著資金的增加，許多政府機構正在尋求加強其醫療基礎設施。政府和私人機構提高意識提升、增加可支配所得和高血壓發病率是預計在整個預測年度推動市場成長率的其他關鍵因素。

治療費用高

使用處方藥、診斷測試和外科手術持續治療動脈粥狀硬化是必要的。這些治療為個人和家庭帶來了巨大的費用。此外，為了應對心臟病和中風等副作用，住院、手術和復原的費用往往很高。許多動脈粥狀硬化患者需要藥物治療來治療疾病並降低併發症的風險。市場擴張受到這些療法的成本和潛在使用期限的限制。

COVID-19 的影響：

COVID-19大流行對動脈粥狀硬化藥物市場產生了負面影響，因為幾家參與資金籌措的公司推遲了針對該疾病的創新動脈粥樣硬化藥物的資金和投資。它影響了我。此外，疫情對正在進行的動脈粥狀硬化臨床試驗產生了不利影響，導致臨床試驗延遲，並阻礙了動脈粥狀硬化藥物的全球市場擴張。

預計在預測期內，口服細分市場將是最大的

預計口腔細分市場在預測期內將是最大的。這是由於人們對常規膽固醇檢測和治療以及久坐生活方式的了解增加，這些生活方式與其他疾病（包括糖尿病）的發展有關。此外，黏膜滲透性、藥物溶解度和胃腸道環境穩定性也是口服藥物的優點。結果，需求擴大，有助於動脈硬化治療藥物市場佔有率的擴大。

預計零售藥局領域在預測期內年複合成長率最高

零售藥房領域預計在預測期內年複合成長率最高。這與人們從藥局和零售藥局購買藥品的願望不斷增加有關，因為這些藥局可以提供廉價合理的藥品，並且可以方便地獲得心血管藥物。另一個好處是，前往零售藥局和藥局購買動脈粥狀硬化藥物的顧客有了解處方箋的一切的優勢，這推動了這一領域的成長。

比最大的地區

由於政府和私營部門倡導健康生活方式的配合措施不斷增加，預計北美在預測期內將佔據最大的市場佔有率。由於醫療基礎設施完善、購買力強勁以及動脈粥狀硬化治療產品的接受度不斷提高，該市場預計將擴大。此外，該地區心血管疾病罹患率的上升和社會預防疾病意識的提高正在推動動脈硬化治療的需求並支持市場擴張。

複合年複合成長率最高的地區：

預計亞太地區在預測期內將維持最高的年複合成長率。這是由於該地區製藥公司的存在以及人口大國購買力的不斷增強。由於患有各種心血管疾病的老年人數量不斷增加，市場正在擴大。此外，由於其龐大的人口基數、未滿足的醫療需求和不斷成長的可支配所得，它具有巨大的成長潛力。此外，醫療旅遊的擴張和醫療保健基礎設施的成長正在創造一個盈利的市場。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球動脈硬化市場：依階段

  • 斑塊生長
  • 破壞斑塊
  • 內皮損傷和免疫反應
  • 脂肪紋
  • 其他階段

第6章 全球動脈硬化市場：依治療分類

  • 藥品
    • BETA 受體阻斷藥
    • 血管張力素轉換酶 (Ace) 抑制劑
    • 鈣通道阻斷劑
    • 抗血小板藥物
    • 降低膽固醇藥物
  • 外科手術
    • 纖溶療法
    • 切除術
    • 冠狀動脈繞道術
    • 血管成形術
  • 其他治療方法

第7章 全球動脈粥狀硬化市場：依給藥途徑

  • 胃腸外的
  • 口服

第8章 全球動脈粥狀硬化市場：依配銷通路

  • 零售藥房
  • 網路藥房

第9章 全球動脈粥狀硬化市場：依診斷

  • 多普勒超音波
  • 驗血
  • 腳踝臂指數 (ABI)
  • 超音波心臟檢查
  • 心電圖（ECG）
  • 其他診斷

第10章 全球動脈粥狀硬化市場：依最終用戶分類

  • 專科診所
  • 居家護理
  • 醫院
  • 其他最終用戶

第11章全球動脈粥狀硬化市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第12章進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章公司簡介

  • Boehringer Ingelheim International GmbH.
  • Bayer AG
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Lupin
  • GlaxoSmithKline plc
  • Dr. Reddy's Laboratories Ltd.
  • Allergan
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Sanofi
  • Allergan
  • Eli Lilly and Company
  • AbbVie Inc.
  • Amgen Inc.
  • Gilead Sciences, Inc.
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Private Limited
  • AstraZeneca
  • Merck & Co., Inc.
  • Mylan NV
Product Code: SMRC23983

According to Stratistics MRC, the Global Atherosclerosis Market is growing at a CAGR of 4.24% during the forecast period. Atherosclerosis is the term used to describe the gradual hardening and construction of your arteries brought on by cholesterol plaques lining them. The use of medications to treat high blood pressure and high cholesterol will reduce, if not stop, atherosclerosis. They lessen your risk of experiencing a heart attack or stroke. Bypass surgery includes utilizing a vascular from another region of body or a synthetic tube to redirect blood around a blocked or constricted artery. To dissolve a blood clot, thrombolytic treatment involves injecting a drug into the affected artery. Atherectomy is the process of removing plaque from your arteries using a catheter with a cutting edge at one end.

According to the European Heart Network, cardiovascular disease affects 3.9 million people in Europe each year, with over 1.8 million people dying in the European Union.

Market Dynamics:

Driver:

Increasing prevalence of cardiovascular diseases

It is predicted that the market would develop faster due to the increased frequency of cardiovascular disorders worldwide. Sedentary lifestyles are to blame for the highest incidence of cardiovascular disease in developed nations. Additionally, a rise in the elderly population and a sedentary lifestyle that results in a high frequency of cardiovascular illnesses and growing awareness of available treatments is predicted to boost the market under study.

Restraint:

Side effects associated with atherosclerosis

The risk of cardiovascular events like heart attacks and strokes is increased by atherosclerosis. These occurrences may result in death or serious disability. Peripheral artery disease may be brought on by atherosclerosis in the arteries of the extremities, particularly the legs. This may result in discomfort, numbness, and trouble walking. This can put more stress on the cardiovascular system by making arteries less elastic and raising blood pressure. Growth of the market is anticipated to be hampered by the adverse effects of atherosclerosis and the low effectiveness.

Opportunity:

Increasing infrastructure spending for healthcare

The increase in healthcare spending, which aids in enhancing its infrastructure, is the element driving the market's growth rate. By boosting funds, a number of government agencies seek to enhance the healthcare infrastructure. Rising awareness-raising efforts by both governmental and private organizations, an increase in disposable income, and the high incidence of high blood pressure are other key elements that are projected to boost the market's growth rate throughout the course of the forecast year.

Threat:

High cost of treatment

The continuing treatment of atherosclerosis using prescription drugs, diagnostic exams, and surgical procedures is necessary. These medical treatments can be quite expensive for both individuals and families. Furthermore, the costs of hospitalization, surgery, and rehabilitation are frequently significant when addressing side effects including heart attacks and strokes. To treat their illness and lower the risk of complications, many people with atherosclerosis need medication. The market expansion is being constrained by the cost and potential duration of use of these treatments.

COVID-19 Impact:

The COVID-19 pandemic had a detrimental effect on the market for atherosclerosis medications since it delayed financing from several firms involved in research and development as well as investments in innovative atherosclerosis therapies that target the disease. Additionally, the pandemic had a detrimental effect on the atherosclerosis clinical studies that were in progress, which hampered the expansion of the worldwide market for atherosclerosis medications as a result of the delayed clinical trials.

The oral segment is expected to be the largest during the forecast period

The oral segment is expected to be the largest during the forecast period. This is due to a rise in knowledge about routine cholesterol testing and therapy as well as sedentary lifestyles that have been linked to the onset of other ailments, including diabetes. Additionally, the mucosal permeability, drug solubility, and environmental stability in the gastrointestinal tract are benefits of oral medications. As a result, their demand is larger, which helps the market share growth of medications for atherosclerosis.

The retail pharmacy segment is expected to have the highest CAGR during the forecast period

The retail pharmacy segment is expected to have the highest CAGR during the forecast period. This is linked to a growth in the desire for buying medications from drug shops and retail pharmacies owing to the availability of cheap and reasonably priced medications as well as the simplicity of obtaining cardiovascular medications in these pharmacies. Additionally, customers who visit retail pharmacies and drug shops to buy atherosclerosis meds benefit from the ability to learn all there is to know about the prescriptions, which serves to fuel the segment's expansion.

Region with largest share:

North America is projected to hold the largest market share during the forecast period due to increase in government and private sector efforts to promote healthy lifestyles. The market is anticipated to increase as a result of the well-established healthcare infrastructure, strong buying power, and rising acceptance of atherosclerosis treatment products. In addition, rising cardiovascular disease incidence in the area and increased public awareness of disease prevention are driving up demand for atherosclerosis medications and propelling the market's expansion.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. This is due to the presence of pharmaceutical businesses in the area as well as the increase in the purchasing power of populous nations. The market is expanding as a result of the growing number of elderly people who are suffering from different cardiovascular ailments. Additionally, because of the huge population base, unmet medical demands, and rise in disposable income, it has a great growth potential. Additionally, a profitable market is created by the expansion of medical tourism and growing healthcare infrastructure.

Key players in the market:

Some of the key players in Atherosclerosis Market include: Boehringer Ingelheim International GmbH., Bayer AG, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Lupin, GlaxoSmithKline plc, Dr. Reddy's Laboratories Ltd. , Allergan, F. Hoffmann-La Roche Ltd., Novartis AG, Bristol-Myers Squibb Company, Sanofi, Allergan, Eli Lilly and Company, AbbVie Inc., Amgen Inc., Gilead Sciences, Inc., Hikma Pharmaceuticals PLC, Johnson & Johnson Private Limited, AstraZeneca, Merck & Co., Inc. and Mylan N.V.

Key Developments:

In September 2022, Novo Nordisk has entered into a new strategic cooperation with Microsoft to accelerate medication research and development via the use of big data and artificial intelligence (AI). The team will employ artificial intelligence to construct models that can predict a person's risk of getting atherosclerosis or arterial plaque development.

In August 2022, AstraZeneca and Merck, known as MSD outside the United States and Canada, announced that the European Commission (EC) has approved LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2 mutations (gBRCAm) and HER2-negative high-risk early breast cancer who have previously received neoadjuvant or adjuvant chemotherapy.

In December 2021, Novartis announced the US Food and Drug Administration (FDA) approval of Leqvio, the first and only small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol with two doses a year, after an initial dose and one at three months.

Stages Covered:

  • Plaque Growth
  • Plaque Rupture
  • Endothelial Damage and Immune Response
  • Fatty Streak
  • Other Stages

Treatments Covered:

  • Medication
  • Surgery
  • Other Treatments

Route of Administrations Covered:

  • Parenteral
  • Oral

Distribution Channels Covered:

  • Retail Pharmacy
  • Online Pharmacy

Diagnosis Covered:

  • Doppler Ultrasound
  • Blood Tests
  • Ankle-brachial Index (ABI)
  • Echocardiogram
  • Electrocardiogram (ECG)
  • Other Diagnosis

End Users Covered:

  • Specialty Clinics
  • Homecare
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Atherosclerosis Market, By Stage

  • 5.1 Introduction
  • 5.2 Plaque Growth
  • 5.3 Plaque Rupture
  • 5.4 Endothelial Damage and Immune Response
  • 5.5 Fatty Streak
  • 5.6 Other Stages

6 Global Atherosclerosis Market, By Treatment

  • 6.1 Introduction
  • 6.2 Medication
    • 6.2.1 Beta Blockers
    • 6.2.2 Angiotensin-Converting Enzyme (Ace) Inhibitors
    • 6.2.3 Calcium Channel Blockers
    • 6.2.4 Anti-Platelet Drugs
    • 6.2.5 Cholesterol Lowering Medications
  • 6.3 Surgery
    • 6.3.1 Fibrinolytic therapy
    • 6.3.2 Endarterectomy
    • 6.3.3 Coronary artery bypass surgery
    • 6.3.4 Angioplasty
  • 6.4 Other Treatments

7 Global Atherosclerosis Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Parenteral
  • 7.3 Oral

8 Global Atherosclerosis Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Retail Pharmacy
  • 8.3 Online Pharmacy

9 Global Atherosclerosis Market, By Diagnosis

  • 9.1 Introduction
  • 9.2 Doppler Ultrasound
  • 9.3 Blood Tests
  • 9.4 Ankle-brachial Index (ABI)
  • 9.5 Echocardiogram
  • 9.6 Electrocardiogram (ECG)
  • 9.7 Other Diagnosis

10 Global Atherosclerosis Market, By End User

  • 10.1 Introduction
  • 10.2 Specialty Clinics
  • 10.3 Homecare
  • 10.4 Hospitals
  • 10.5 Other End Users

11 Global Atherosclerosis Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Boehringer Ingelheim International GmbH.
  • 13.2 Bayer AG
  • 13.3 Teva Pharmaceutical Industries Ltd.
  • 13.4 Pfizer Inc.
  • 13.5 Lupin
  • 13.6 GlaxoSmithKline plc
  • 13.7 Dr. Reddy's Laboratories Ltd.
  • 13.8 Allergan
  • 13.9 F. Hoffmann-La Roche Ltd.
  • 13.10 Novartis AG
  • 13.11 Bristol-Myers Squibb Company
  • 13.12 Sanofi
  • 13.13 Allergan
  • 13.14 Eli Lilly and Company
  • 13.15 AbbVie Inc.
  • 13.16 Amgen Inc.
  • 13.17 Gilead Sciences, Inc.
  • 13.18 Hikma Pharmaceuticals PLC
  • 13.19 Johnson & Johnson Private Limited
  • 13.20 AstraZeneca
  • 13.21 Merck & Co., Inc.
  • 13.22 Mylan N.V.

List of Tables

  • Table 1 Global Atherosclerosis Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Atherosclerosis Market Outlook, By Stage (2021-2030) ($MN)
  • Table 3 Global Atherosclerosis Market Outlook, By Plaque Growth (2021-2030) ($MN)
  • Table 4 Global Atherosclerosis Market Outlook, By Plaque Rupture (2021-2030) ($MN)
  • Table 5 Global Atherosclerosis Market Outlook, By Endothelial Damage and Immune Response (2021-2030) ($MN)
  • Table 6 Global Atherosclerosis Market Outlook, By Fatty Streak (2021-2030) ($MN)
  • Table 7 Global Atherosclerosis Market Outlook, By Other Stages (2021-2030) ($MN)
  • Table 8 Global Atherosclerosis Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 9 Global Atherosclerosis Market Outlook, By Medication (2021-2030) ($MN)
  • Table 10 Global Atherosclerosis Market Outlook, By Beta Blockers (2021-2030) ($MN)
  • Table 11 Global Atherosclerosis Market Outlook, By Angiotensin-Converting Enzyme (Ace) Inhibitors (2021-2030) ($MN)
  • Table 12 Global Atherosclerosis Market Outlook, By Calcium Channel Blockers (2021-2030) ($MN)
  • Table 13 Global Atherosclerosis Market Outlook, By Anti-Platelet Drugs (2021-2030) ($MN)
  • Table 14 Global Atherosclerosis Market Outlook, By Cholesterol Lowering Medications (2021-2030) ($MN)
  • Table 15 Global Atherosclerosis Market Outlook, By Surgery (2021-2030) ($MN)
  • Table 16 Global Atherosclerosis Market Outlook, By Fibrinolytic therapy (2021-2030) ($MN)
  • Table 17 Global Atherosclerosis Market Outlook, By Endarterectomy (2021-2030) ($MN)
  • Table 18 Global Atherosclerosis Market Outlook, By Coronary artery bypass surgery (2021-2030) ($MN)
  • Table 19 Global Atherosclerosis Market Outlook, By Angioplasty (2021-2030) ($MN)
  • Table 20 Global Atherosclerosis Market Outlook, By Other Treatments (2021-2030) ($MN)
  • Table 21 Global Atherosclerosis Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 22 Global Atherosclerosis Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 23 Global Atherosclerosis Market Outlook, By Oral (2021-2030) ($MN)
  • Table 24 Global Atherosclerosis Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 25 Global Atherosclerosis Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 26 Global Atherosclerosis Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 27 Global Atherosclerosis Market Outlook, By Diagnosis (2021-2030) ($MN)
  • Table 28 Global Atherosclerosis Market Outlook, By Doppler Ultrasound (2021-2030) ($MN)
  • Table 29 Global Atherosclerosis Market Outlook, By Blood Tests (2021-2030) ($MN)
  • Table 30 Global Atherosclerosis Market Outlook, By Ankle-brachial Index (ABI) (2021-2030) ($MN)
  • Table 31 Global Atherosclerosis Market Outlook, By Echocardiogram (2021-2030) ($MN)
  • Table 32 Global Atherosclerosis Market Outlook, By Electrocardiogram (ECG) (2021-2030) ($MN)
  • Table 33 Global Atherosclerosis Market Outlook, By Other Diagnosis (2021-2030) ($MN)
  • Table 34 Global Atherosclerosis Market Outlook, By End User (2021-2030) ($MN)
  • Table 35 Global Atherosclerosis Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 36 Global Atherosclerosis Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 37 Global Atherosclerosis Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 38 Global Atherosclerosis Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.